Maria Vedechkina, Joni Holmes, Varun Warrier, Duncan E Astle
{"title":"A common neural signature between genetic and environmental risk for mental illness.","authors":"Maria Vedechkina, Joni Holmes, Varun Warrier, Duncan E Astle","doi":"10.1038/s41398-025-03513-1","DOIUrl":null,"url":null,"abstract":"<p><p>Not everyone is equally likely to experience mental illness. What is the contribution of an individual's genetic background and experiences of childhood adversity to that likelihood? And how do these risk factors interact at the level of the brain? This study explores these questions by investigating the relationship between genetic liability for mental illness, childhood adversity, and cortico-limbic connectivity in a large developmental sample drawn from the ABCD cohort (N = 6535). Canonical Correlation Analysis - a multivariate data-reduction technique - revealed two genetic dimensions of mental illness from the polygenic risk scores for ADHD, Anxiety, Depression, and Psychosis. The first dimension represented liability for broad psychopathology which was positively correlated with adversity. The second dimension represented neurodevelopmental-specific risk which negatively interacted with adversity, suggesting that neurodevelopmental symptoms may arise from unique combinations of genetic and environmental factors that differ from other symptom domains. Next, we investigated the cortico-limbic signature of adversity and genetic liability using Partial Least Squares. We found that the neural correlates of adversity broadly mirrored those of genetic liability, with adversity capturing most of the shared variance. These novel findings suggest that genetic and environmental risk overlap in the neural connections that underlie mental health symptomatology.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"305"},"PeriodicalIF":6.2000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03513-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Not everyone is equally likely to experience mental illness. What is the contribution of an individual's genetic background and experiences of childhood adversity to that likelihood? And how do these risk factors interact at the level of the brain? This study explores these questions by investigating the relationship between genetic liability for mental illness, childhood adversity, and cortico-limbic connectivity in a large developmental sample drawn from the ABCD cohort (N = 6535). Canonical Correlation Analysis - a multivariate data-reduction technique - revealed two genetic dimensions of mental illness from the polygenic risk scores for ADHD, Anxiety, Depression, and Psychosis. The first dimension represented liability for broad psychopathology which was positively correlated with adversity. The second dimension represented neurodevelopmental-specific risk which negatively interacted with adversity, suggesting that neurodevelopmental symptoms may arise from unique combinations of genetic and environmental factors that differ from other symptom domains. Next, we investigated the cortico-limbic signature of adversity and genetic liability using Partial Least Squares. We found that the neural correlates of adversity broadly mirrored those of genetic liability, with adversity capturing most of the shared variance. These novel findings suggest that genetic and environmental risk overlap in the neural connections that underlie mental health symptomatology.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.